BR122016015852B8 - peptídeos de liberação de hormônio do crescimento, seu uso e método de determinação da habilidade de um composto em se ligar a um receptor de ghs - Google Patents
peptídeos de liberação de hormônio do crescimento, seu uso e método de determinação da habilidade de um composto em se ligar a um receptor de ghsInfo
- Publication number
- BR122016015852B8 BR122016015852B8 BR122016015852A BR122016015852A BR122016015852B8 BR 122016015852 B8 BR122016015852 B8 BR 122016015852B8 BR 122016015852 A BR122016015852 A BR 122016015852A BR 122016015852 A BR122016015852 A BR 122016015852A BR 122016015852 B8 BR122016015852 B8 BR 122016015852B8
- Authority
- BR
- Brazil
- Prior art keywords
- bzl
- bind
- ability
- compound
- determining
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 102100033367 Appetite-regulating hormone Human genes 0.000 title 1
- 101710119601 Growth hormone-releasing peptides Proteins 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- ONOURAAVVKGJNM-SCZZXKLOSA-N (2s,3r)-2-azaniumyl-3-phenylmethoxybutanoate Chemical compound [O-]C(=O)[C@@H]([NH3+])[C@@H](C)OCC1=CC=CC=C1 ONOURAAVVKGJNM-SCZZXKLOSA-N 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000000816 peptidomimetic Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Reproductive Health (AREA)
- Crystallography & Structural Chemistry (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40226302P | 2002-08-09 | 2002-08-09 | |
| US60/402,263 | 2002-08-09 | ||
| BRPI0313273A BRPI0313273B8 (pt) | 2002-08-09 | 2003-08-08 | peptídeos de liberação de hormônio do crescimento, seu uso e método de determinação da habilidade de um composto em se ligar a um receptor de ghs |
| PCT/US2003/024834 WO2004014415A1 (en) | 2002-08-09 | 2003-08-08 | Growth hormone releasing peptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR122016015852B1 BR122016015852B1 (pt) | 2018-06-19 |
| BR122016015852B8 true BR122016015852B8 (pt) | 2021-07-27 |
Family
ID=31715820
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR122016015852A BR122016015852B8 (pt) | 2002-08-09 | 2003-08-08 | peptídeos de liberação de hormônio do crescimento, seu uso e método de determinação da habilidade de um composto em se ligar a um receptor de ghs |
| BRPI0313273A BRPI0313273B8 (pt) | 2002-08-09 | 2003-08-08 | peptídeos de liberação de hormônio do crescimento, seu uso e método de determinação da habilidade de um composto em se ligar a um receptor de ghs |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0313273A BRPI0313273B8 (pt) | 2002-08-09 | 2003-08-08 | peptídeos de liberação de hormônio do crescimento, seu uso e método de determinação da habilidade de um composto em se ligar a um receptor de ghs |
Country Status (22)
| Country | Link |
|---|---|
| US (7) | US7456253B2 (https=) |
| EP (2) | EP2130548A3 (https=) |
| JP (2) | JP4365319B2 (https=) |
| KR (1) | KR100967572B1 (https=) |
| CN (3) | CN101108875A (https=) |
| AR (2) | AR040965A1 (https=) |
| AT (1) | ATE447411T1 (https=) |
| AU (1) | AU2003259062B2 (https=) |
| BR (2) | BR122016015852B8 (https=) |
| CA (1) | CA2494300C (https=) |
| CZ (1) | CZ20041254A3 (https=) |
| DE (1) | DE60329923D1 (https=) |
| DK (1) | DK1542716T3 (https=) |
| ES (1) | ES2334223T3 (https=) |
| IL (1) | IL165998A (https=) |
| MX (1) | MXPA05000974A (https=) |
| NO (1) | NO20050205L (https=) |
| PL (1) | PL212138B1 (https=) |
| RU (2) | RU2323941C2 (https=) |
| SG (1) | SG177006A1 (https=) |
| TW (1) | TWI331922B (https=) |
| WO (1) | WO2004014415A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI331922B (en) * | 2002-08-09 | 2010-10-21 | Ipsen Pharma Sas | Growth hormone releasing peptides |
| WO2004027064A2 (en) * | 2002-09-18 | 2004-04-01 | Centre Hospitalier De L'universite De Montreal (Chum) | Ghrh analogues |
| WO2004071448A2 (en) * | 2003-02-12 | 2004-08-26 | Transtech Pharma Inc. | Substituted azole derivatives as inhibitors of protein tyrosine phosphatases |
| WO2006045314A2 (en) * | 2004-10-27 | 2006-05-04 | Gastrotech Pharma A/S | Use of a growth hormone secretatogue for increasing or maintaining lean body mass and/or for treatment of chronic obstructive pulmonary disease |
| JP2008521840A (ja) * | 2004-11-30 | 2008-06-26 | ガストロテック・ファルマ・アクティーゼルスカブ | 成長ホルモン分泌促進物質レセプター１ａリガンド |
| US8138218B2 (en) | 2005-07-22 | 2012-03-20 | Ipsen Pharma S.A.S. | Growth hormone secretagogues |
| ES2740108T3 (es) * | 2005-09-29 | 2020-02-05 | Ipsen Pharma | Composición para uso en el tratamiento de dismotilidad gastrointestinal |
| EP1818061A1 (en) * | 2005-12-02 | 2007-08-15 | Charite-Universitätsmedizin Berlin | Use of ghrelin for stimulating hair growth |
| CU23592A1 (es) * | 2006-02-28 | 2010-11-11 | Ct Ingenieria Genetica Biotech | Método para prevenir y eliminar las fibrosis y otras formas de depósito patológico en los tejidos aplicando el péptido secretagogo ghrp-6 |
| EP2012809B1 (en) * | 2006-03-10 | 2013-05-22 | Ipsen Pharma | Use of a ghrelin agonist to improve the catabolic effects of glucocorticoid treatment |
| WO2007127457A2 (en) * | 2006-04-28 | 2007-11-08 | The Administrators Of The Tulane Educational Fund | Ghrelin/growth hormone releasing peptide/growth hormone secretatogue receptor antagonists and uses thereof |
| AU2007300526B2 (en) * | 2006-09-27 | 2011-07-21 | Ipsen Pharma S.A.S. | Analogs of ghrelin substituted at the N-terminal |
| KR20090119785A (ko) | 2007-03-12 | 2009-11-19 | 유키지루시 뉴교 가부시키가이샤 | 성장 호르몬 분비 촉진제 |
| TW200916113A (en) * | 2007-08-08 | 2009-04-16 | Sod Conseils Rech Applic | Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue |
| WO2009108364A2 (en) * | 2008-02-27 | 2009-09-03 | Ipsen Pharma S.A.S. | Antagonistic analogues of ghrh |
| US9724381B2 (en) | 2009-05-12 | 2017-08-08 | The Administrators Of The Tulane Educational Fund | Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof |
| MX343499B (es) * | 2010-03-15 | 2016-11-08 | Ipsen Pharma Sas | Composiciones farmaceuticas de ligandos receptores de secretagoga de la hormona de crecimiento. |
| AR088392A1 (es) * | 2011-10-18 | 2014-05-28 | Aileron Therapeutics Inc | Macrociclos peptidomimeticos |
| UA115542C2 (uk) * | 2011-12-23 | 2017-11-27 | Іпсен Мануфекчерінг Айрленд Лімітед | Процес синтезу терапевтичних пептидів |
| US10039813B2 (en) | 2012-02-07 | 2018-08-07 | Massachusetts Institute Of Technology | Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness |
| EP2705835A1 (en) * | 2012-06-08 | 2014-03-12 | Ipsen Pharma S.A.S. | Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release |
| WO2014144231A1 (en) | 2013-03-15 | 2014-09-18 | Massachusetts Institute Of Technology | Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness |
| US9119832B2 (en) | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
| AU2015227278A1 (en) | 2014-03-04 | 2016-10-06 | Allergan Gi Corp. | Process for the liquid phase synthesis of H-Inp-(D)Bal-(D)Trp-Phe-Apc-NH2, and pharmaceutically acceptable salts thereof |
| WO2016138099A1 (en) | 2015-02-24 | 2016-09-01 | Massachusetts Institute Of Technology | Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness |
| WO2017075535A1 (en) | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
| US10111929B1 (en) * | 2017-04-07 | 2018-10-30 | Ez Ip, Llc | Growth hormone releasing factor analogs and uses |
| CN113072617B (zh) * | 2021-03-30 | 2023-08-08 | 成都诺和晟泰生物科技有限公司 | 一种多肽化合物及其应用 |
| CN113045625B (zh) * | 2021-03-30 | 2023-11-07 | 成都诺和晟泰生物科技有限公司 | 作为生长激素促分泌素受体激动剂的多肽及其应用 |
| CN114805487B (zh) * | 2022-06-07 | 2024-03-12 | 成都诺和晟泰生物科技有限公司 | 一种多肽化合物及其应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5264565A (en) | 1991-01-22 | 1993-11-23 | Affymax Technologies, N.V. | Nucleic acid encoding the D2 /Ml chimeric receptor |
| JP3131049B2 (ja) * | 1992-09-30 | 2001-01-31 | マツダ株式会社 | 車両のサスペンション装置 |
| HU224345B1 (hu) | 1993-12-23 | 2005-08-29 | Novo Nordisk A/S. | Növekedési hormont felszabadító tulajdonságú peptidek, ezeket hatóanyagként tartalmazó gyógyszerkészítmények és alkalmazásuk |
| US7067326B2 (en) * | 1994-01-13 | 2006-06-27 | The Trustees Of Columbia University In The City Of New York | Synthetic receptors, libraries and uses thereof |
| RU2110275C1 (ru) * | 1994-09-09 | 1998-05-10 | Дейгин Владислав Исакович | Способ получения пептида, обладающего анаболической активностью, стимулирующего увеличение массы тела, развитие эпидермального слоя и роста волосяного покрова |
| JP3810083B2 (ja) * | 1994-09-27 | 2006-08-16 | アーダナ・バイオサイエンス・リミテツド | 成長因子の放出を促進し得る２−アルキルトリプトファン含有ペプチド化合物 |
| US20020111461A1 (en) * | 1999-05-21 | 2002-08-15 | Todd C. Somers | Low molecular weight peptidomimetic growth hormone secretagogues |
| US5798337A (en) | 1994-11-16 | 1998-08-25 | Genentech, Inc. | Low molecular weight peptidomimetic growth hormone secretagogues |
| US5776718A (en) * | 1995-03-24 | 1998-07-07 | Arris Pharmaceutical Corporation | Reversible protease inhibitors |
| BR9608909A (pt) | 1995-06-22 | 1999-03-02 | Novo Nordisk As | Composto composição farmacêutica processos para estimular a liberação do hormônio do crescimento da patuitária e aumentar a velocidade e extensão do crescimento dos animais para aumentar a produção de leite ou lã de animais ou para para doenças e uso do composto |
| DE69637587D1 (de) | 1995-07-26 | 2008-08-21 | Astrazeneca Ab | Chimäre rezeptoren und verfahren zur identifizieren verbindungen mit einem aktivität als metabotropischen glutamatrezeptoren sowie verwendung solcher verbindungen in der behandlung von neurologischer erkrankungen und neurologischenstörrungen |
| US6124263A (en) * | 1998-11-16 | 2000-09-26 | Asta Medica Ag | Treatment of tumors by administration of growth hormone releasing compounds and their antagonists |
| US5932548A (en) * | 1998-06-03 | 1999-08-03 | Deghenghi; Romano | Lysine containing peptides for treatment of heart disease |
| AU5671099A (en) * | 1998-08-14 | 2000-03-06 | The Administrators Of The Tulane Eductional Fund | Compounds having growth hormone releasing activity |
| KR100827973B1 (ko) | 1999-07-23 | 2008-05-21 | 겐지 간가와 | 신규 펩티드 |
| US20020187938A1 (en) | 2000-07-24 | 2002-12-12 | Romano Deghenghi | Ghrelin antagonists |
| TWI331922B (en) * | 2002-08-09 | 2010-10-21 | Ipsen Pharma Sas | Growth hormone releasing peptides |
| WO2006045314A2 (en) | 2004-10-27 | 2006-05-04 | Gastrotech Pharma A/S | Use of a growth hormone secretatogue for increasing or maintaining lean body mass and/or for treatment of chronic obstructive pulmonary disease |
| ES2740108T3 (es) * | 2005-09-29 | 2020-02-05 | Ipsen Pharma | Composición para uso en el tratamiento de dismotilidad gastrointestinal |
| EP2012809B1 (en) * | 2006-03-10 | 2013-05-22 | Ipsen Pharma | Use of a ghrelin agonist to improve the catabolic effects of glucocorticoid treatment |
| TW200916113A (en) * | 2007-08-08 | 2009-04-16 | Sod Conseils Rech Applic | Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue |
-
2003
- 2003-08-06 TW TW092121571A patent/TWI331922B/zh not_active IP Right Cessation
- 2003-08-08 BR BR122016015852A patent/BR122016015852B8/pt not_active IP Right Cessation
- 2003-08-08 DK DK03785034.4T patent/DK1542716T3/da active
- 2003-08-08 CN CNA2007101279712A patent/CN101108875A/zh active Pending
- 2003-08-08 US US10/484,473 patent/US7456253B2/en not_active Expired - Lifetime
- 2003-08-08 JP JP2004527871A patent/JP4365319B2/ja not_active Expired - Fee Related
- 2003-08-08 MX MXPA05000974A patent/MXPA05000974A/es active IP Right Grant
- 2003-08-08 EP EP09171176A patent/EP2130548A3/en not_active Withdrawn
- 2003-08-08 SG SG2007033848A patent/SG177006A1/en unknown
- 2003-08-08 RU RU2005106236/04A patent/RU2323941C2/ru active
- 2003-08-08 EP EP03785034A patent/EP1542716B1/en not_active Expired - Lifetime
- 2003-08-08 PL PL373605A patent/PL212138B1/pl unknown
- 2003-08-08 CN CNA038186810A patent/CN1674927A/zh active Pending
- 2003-08-08 CZ CZ20041254A patent/CZ20041254A3/cs unknown
- 2003-08-08 KR KR1020057001094A patent/KR100967572B1/ko not_active Expired - Fee Related
- 2003-08-08 AT AT03785034T patent/ATE447411T1/de active
- 2003-08-08 AU AU2003259062A patent/AU2003259062B2/en not_active Ceased
- 2003-08-08 CN CN201210307885.0A patent/CN102850436B/zh not_active Expired - Fee Related
- 2003-08-08 WO PCT/US2003/024834 patent/WO2004014415A1/en not_active Ceased
- 2003-08-08 ES ES03785034T patent/ES2334223T3/es not_active Expired - Lifetime
- 2003-08-08 DE DE60329923T patent/DE60329923D1/de not_active Expired - Lifetime
- 2003-08-08 AR ARP030102883A patent/AR040965A1/es active IP Right Grant
- 2003-08-08 BR BRPI0313273A patent/BRPI0313273B8/pt not_active IP Right Cessation
- 2003-08-08 CA CA2494300A patent/CA2494300C/en not_active Expired - Fee Related
-
2004
- 2004-12-27 IL IL165998A patent/IL165998A/en active IP Right Grant
-
2005
- 2005-01-13 NO NO20050205A patent/NO20050205L/no not_active Application Discontinuation
-
2007
- 2007-12-03 RU RU2007145026/04A patent/RU2007145026A/ru not_active Application Discontinuation
-
2008
- 2008-03-31 AR ARP080101348A patent/AR062801A2/es not_active Application Discontinuation
- 2008-06-09 US US12/157,224 patent/US8377865B2/en not_active Expired - Fee Related
-
2009
- 2009-01-26 JP JP2009014262A patent/JP5025668B2/ja not_active Expired - Fee Related
-
2013
- 2013-01-04 US US13/734,314 patent/US8859729B2/en not_active Expired - Fee Related
-
2014
- 2014-10-09 US US14/510,188 patent/US9409948B2/en not_active Expired - Fee Related
-
2016
- 2016-07-07 US US15/203,956 patent/US20160311855A1/en not_active Abandoned
-
2017
- 2017-08-29 US US15/688,979 patent/US20170362275A1/en not_active Abandoned
-
2019
- 2019-09-25 US US16/581,960 patent/US20200017548A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR122016015852B8 (pt) | peptídeos de liberação de hormônio do crescimento, seu uso e método de determinação da habilidade de um composto em se ligar a um receptor de ghs | |
| US9315545B2 (en) | Hepcidin mimetic peptides and uses thereof | |
| ES2203823T3 (es) | Analogos heptapeptidicos de oxitocina. | |
| SG172290A1 (en) | Dipeptide linked medicinal agents | |
| EP2588127A1 (en) | Dipeptide linked medicinal agents | |
| WO2011038066A4 (en) | Novel npr-b agonists | |
| AU2014302122A1 (en) | Stable liquid formulation of AMG 416 (Velcalcetide) | |
| HK1213785A1 (zh) | 血管紧张素的口服制剂 | |
| US20230110554A1 (en) | Methods and compositions for treatment of coronavirus infection | |
| CA2912635A1 (en) | Angiotensin peptides in treating marfan syndrome and related disorders | |
| AU685292B2 (en) | Tri-, tetra-, penta-, and polypeptides and their therapeutic use as a n antidepressant agent | |
| JP2016026193A (ja) | 点眼剤 | |
| Reile et al. | New antagonists of bombesin gastrin-releasing Peptide with C-terminal leu-psi-(ch2n) tac-nh2 | |
| BRPI0500392A (pt) | peptìdeos de liberação de hormÈnio do crescimento | |
| US20160199436A1 (en) | Methods and compositions for the treatment of amyotrophic lateral sclerosis | |
| US20080194467A1 (en) | Cancer treatment methods using cadherin antagonists in combination with anticancer agents | |
| US5071836A (en) | Competitive gonadoliberin antagonists | |
| Gerdin et al. | Structural requirements for microvascular permeability-increasing ability of peptides: Studies on analogues of a fibrinogen pentapeptide fragment | |
| WO2026080405A1 (en) | Injectable formulations for non-naturally occurring melanocortin analogs | |
| WO2021152463A1 (ru) | Фармацевтическая композиция и способ еe изготовления | |
| WO2026080412A1 (en) | Formulation for oral administration of non-naturally occurring melanocortin analogs for modulating kidney function and/or glucose uptake | |
| WO2024163598A2 (en) | Peptides comprising thioester groups, including depsipeptide thioesters, methods of making, and use thereof | |
| WO2026080395A1 (en) | Formulation for oral administration of non-naturally occurring melanocortin analogs for treating substance use disorders and/or modulating diabetes | |
| AR030224A1 (es) | Analogos de bombesina, para el tratamiento de cancer, un procedimiento de sintesis de fase solida, una composicion farmaceutica y el uso de dichos peptidos para la manufactura de un medicamento. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] | ||
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/08/2003, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERNETA A 19A ANUIDADE |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: MANUTENCAO DA EXTINCAO - ART. 78 INCISO IV DA LPI |